## MOA
- 抑制 mucopeptide 生合成
	- 結合 D-alanine-D-alanine terminals of the uridine diphosphate-N-acetyl-muramyl peptides
## SAR
- 結構
	- a glycosylated hexapeptide chain
	- pyrogallol ester linkage to glucose and vancosamine
		- ![[Pasted image 20230503001757.png|100]]![[Pasted image 20230503002126.png|100]]
	- five benzene ring
## 特色
- from Streptomyces orientalis 發酵
- [[Bacteriostatic and bactericidal|bactericidal]] 
- 抗藥性
	- mutation in pentapeptide chain of cell wall building block
		- Terminal D-alanine replaced by D-lactate
		- Peptide link replaced by ester link
		- Loss of NH (HBD)
		- Weakens binding affinity of vancomycin with ‘tail’
		- Lactate acts as a leaving group in cell wall synthesis
	- Staphylococcus aureus (VRSA)
	- enterococci (VRE)
- Side effects
	- 高劑量注射造成 anaphylactoid reactions 類過敏反應
		- hypotension, wheezing, dyspnea 呼吸困難, urticaria 蕁麻疹, and pruritus 瘙癢症
	- nephrotoxicity 腎毒性 and auditory nerve damage, phlebitis 靜脈炎，Ototoxicity
	- Red-man syndrome
		- drug rash (histamine release)
## 用途
- 對 G-(+) cocci，streptococci, staphylococci, pneumococci 活性
	- endocarditis 心內膜炎
- 對 coagulase negative staphylococci and methicillin-resistant Staphylococcus aureus (MRSA) 活性
- 口服對 Clostridium difficile 活性
- 對 G-(-) 無活性
	- 除了 Neisseria spp

![[Chemical-structure-of-vancomycin-The-disaccharide-composed-of-vancosamine-and-glucose.png]]